BMS Presents Results of Opdivo (nivolumab) + CT or Yervoy (ipilimumab) in P-III CheckMate -648 Trial for Unresectable Advanced or Metastatic ESCC at ASCO 2021

 BMS Presents Results of Opdivo (nivolumab) + CT or Yervoy (ipilimumab) in P-III CheckMate -648 Trial for Unresectable Advanced or Metastatic ESCC at ASCO 2021

BMS Presents Results of Opdivo (nivolumab) + CT or Yervoy (ipilimumab) in P-III CheckMate -648 Trial for Unresectable Advanced or Metastatic ESCC at ASCO 2021

Shots:

  • The P-III CheckMate -648 trial evaluating Opdivo + CT or Opdivo (3 mg/kg, q2w) + Yervoy (1 mg/kg, q6w up to 24mos.) in patients with unresectable advanced or metastatic ESCC
  • Results: Both combinations showed OS benefits over CT in PD-L1 positive & all-randomized populations, m-OS for Opdivo + CT (13.7 vs 9.1 mos. & 13.2 vs 10.7 mos.) & for Opdivo + CT (3.7 vs 9.1 mos. & 2.8 vs 10.7 mos.); mDoR (8.4 vs 11.8 mos.) & 5.7 mos. for CT alone; ORR (53% vs 35%) & 20% for CT alone
  • Additionally, Opdivo + CT showed improvement in PFS with an m-PFS (6.9 vs 4.4 mos.) while Opdivo + Yervoy failed to meet its 1EPs of PFS, safety profiles were consistent with previously reported for other tumors

Click here to­ read full press release/ article | Ref: Businesswire | Image: Fierce Pharma

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post